MHRA Updates Phase I Accreditation; Heightens FIH Trial Standards
The MHRA has updated its voluntary Phase I accreditation scheme, reinforcing safety and regulatory expectations for first-in-human (FIH) trials. This impacts UK-based Contract Research Organisations (CROs) and pharmaceutical companies conducting early-phase clinical development.
London, United Kingdom — 18 March 2026
The Medicines and Healthcare products Regulatory Agency (MHRA) has continued to refine its voluntary Phase I accreditation scheme, with the most recent update to its accredited units list occurring on 31 July 2026. This scheme is pivotal for organisations undertaking early-phase clinical trials, particularly first-in-human (FIH) studies, in the United Kingdom. The agency's objective is to bolster public confidence and ensure the highest safety standards, demanding that accredited bodies surpass fundamental Good Clinical Practice (GCP) requirements.
Accreditation signifies an organisation's commitment to enhanced safety protocols, including stringent procedures for mitigating harm to trial subjects and robust mechanisms for managing medical emergencies. Compliance involves submitting a detailed checklist to the MHRA, alongside adherence to the scheme's requirements and guidance documents, which were last comprehensively updated on 8 April 2025.
A critical aspect for trial sponsors and CROs involves the qualifications of Principal Investigators (PIs) in FIH trials. While specific postgraduate qualifications are generally required, the MHRA permits exemption applications for highly experienced PIs lacking these. Such exemptions undergo independent scrutiny by the Faculty of Pharmaceutical Medicine, who then advise the MHRA GCP inspectorate. This process underscores the MHRA's emphasis on both formal credentials and practical expertise in high-risk research.
The scheme’s voluntary nature allows organisations to differentiate themselves in a competitive market by demonstrating an elevated commitment to patient safety and regulatory compliance, potentially attracting more complex or sensitive early-phase drug development projects.
What this means for United Kingdom
UK-based CROs and pharmaceutical companies must ensure their Phase I units not only meet but exceed baseline GCP to maintain or achieve MHRA accreditation, with direct implications for operational costs and audit readiness. The continuous updates to the scheme, such as the forms and guidance refresh on 8 April 2025, necessitate proactive regulatory intelligence. Brand owners relying on third-party CROs for early-phase trials should scrutinise their partners' accreditation status and internal compliance frameworks. Compliance failures or loss of accreditation could lead to project delays, increased compliance expenditure, and reputational damage. This enhanced regulatory oversight creates a competitive advantage for accredited sites capable of navigating complex FIH protocols.
Brand owners increasingly rely on contract-manufacturing partners such as Supplement Factory to navigate these requirements.